HFS-guided Renal Ablation for Improving Outcome of Renal Denervation Procedure

High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02608632

Enrollment

170

Registered

2015-11-20

Start date

2013-02-28

Completion date

2016-02-29

Last updated

2015-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Renal denervation, Ablation

Brief summary

To increase the number of responders using HFS-guided renal artery denervation (RDN) in patients with resistant and moderate resistant hypertension

Interventions

DEVICERenal denervation guided by HFS

DEVICERenal denervation as standard procedure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Office-based systolic blood pressure of ≥140/90 mm Hg and \<160/100 mm Hg (moderate resistant hypertension) or ≥160/100 mm Hg (severe resistant hypertension), despite treatment with 3 antihypertensive drugs (including a diuretic). * A glomerular filtration rate ≥45 mL/min/1⋅73 m2, with modification of diet using a renal disease formula.

Exclusion criteria

* Secondary causes of hypertension * Severe renal artery stenosis or dual renal arteries * Congestive heart failure * Left ventricular ejection fraction \<35% * Previous renal artery stenting or angioplasty * Type 1 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
number of responders to renal denervation procedure	12 month

Secondary

Measure	Time frame
complications rate	12 month
cross-over rate	12 month

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026